{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Imprime PGG"},{"type":"ChemicalStructureName","name":"poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose beta-glucan"},{"type":"LexicalVariant","name":"PGG Beta-Glucan"},{"type":"CodeName","name":"BTH-1677"},{"type":"CodeName","name":"BTH1677"},{"type":"CodeName","name":"BTH 1677"},{"type":"Synonym","name":"PGG beta-glucan"}],"definition":{"html":"An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.\n","text":"An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C78463","nciConceptName":"Odetiglucan","termId":599816,"name":"odetiglucan","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"odetiglucan"}],"links":null}